Over the objections of Doctors Without Borders, the Indian government has awarded a patent to Pfizer (PFE) for its best-selling Prevnar 13 pneumococcal vaccine, a move the advocacy group says will restrict access to many patients for nearly a decade.
In reaching its decision, the Indian Patent Office determined the Pfizer patent was sufficiently unique to merit protection, even though Doctors Without Borders filed paperwork last year arguing otherwise. The patent “does not meet the inventive step requirement [and] it ought to have been rejected,” the advocacy group wrote in a statement after the government decision was announced.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
